Synovial Fibroblast 3.1: Secretion response of seven primary human synovial fibroblast samples from healthy and rheumatoid arthritis donors to a panel of 3 stimuli and 5 small molecule inhibitors (replicate 1 of 2) - Dataset (ID:20234)
- Detail
- Small Molecules Studied
- Primary Cells Studied
- Proteins Studied
- Unclassified Perturbagens Studied
- Data Columns
- Results
Download: Excel (XLSX), Comma-separated (CSV)
Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | Protein Stimulus | Other Stimulus | Stimulus Concentration | Stimulus Conc Unit | ExpPlate | Measured Protein | Measured Protein MFI (a.u.) | Bead Count |
---|---|---|---|---|---|---|---|---|---|---|---|
N2645 | 5z-7-oxozeaenol | 0.6 | uM | TNF-a | 100 | ng/mL | 2 | LIF | 47.0 | 43 | |
N2645 | IKK16 | 2.0 | uM | TNF-a | 100 | ng/mL | 2 | LIF | 41.0 | 29 | |
RA2708 | 5z-7-oxozeaenol | 0.6 | uM | TNF-a | 100 | ng/mL | 2 | LIF | 42.0 | 49 | |
RA2708 | IKK16 | 2.0 | uM | TNF-a | 100 | ng/mL | 2 | LIF | 48.0 | 45 | |
RA2159 | Tofacitinib | 0.3 | uM | TNF-a | 100 | ng/mL | 2 | LIF | 49.0 | 31 | |
RA2159 | TNF-a | 100 | ng/mL | 2 | LIF | 45.0 | 32 | ||||
N2645 | Tofacitinib | 0.3 | uM | TNF-a | 100 | ng/mL | 2 | LIF | 70.5 | 30 | |
N2645 | TNF-a | 100 | ng/mL | 2 | LIF | 49.5 | 38 | ||||
RA2708 | Tofacitinib | 0.3 | uM | TNF-a | 100 | ng/mL | 2 | LIF | 52.0 | 33 | |
RA2708 | TNF-a | 100 | ng/mL | 2 | LIF | 61.0 | 29 | ||||
RA2159 | 5z-7-oxozeaenol | 0.6 | uM | IL-1 alpha | 100 | ng/mL | 2 | LIF | 111.0 | 39 | |
RA2159 | IKK16 | 2.0 | uM | IL-1 alpha | 100 | ng/mL | 2 | LIF | 105.0 | 42 | |
N2645 | 5z-7-oxozeaenol | 0.6 | uM | IL-1 alpha | 100 | ng/mL | 2 | LIF | 111.0 | 33 | |
N2645 | IKK16 | 2.0 | uM | IL-1 alpha | 100 | ng/mL | 2 | LIF | 122.0 | 36 | |
RA2708 | 5z-7-oxozeaenol | 0.6 | uM | IL-1 alpha | 100 | ng/mL | 2 | LIF | 103.0 | 31 | |
RA2708 | IKK16 | 2.0 | uM | IL-1 alpha | 100 | ng/mL | 2 | LIF | 118.0 | 25 | |
RA2159 | Tofacitinib | 0.3 | uM | IL-1 alpha | 100 | ng/mL | 2 | LIF | 140.0 | 45 | |
RA2159 | IL-1 alpha | 100 | ng/mL | 2 | LIF | 140.0 | 32 | ||||
N2645 | Tofacitinib | 0.3 | uM | IL-1 alpha | 100 | ng/mL | 2 | LIF | 125.5 | 44 | |
N2645 | IL-1 alpha | 100 | ng/mL | 2 | LIF | 121.0 | 39 | ||||
RA2708 | Tofacitinib | 0.3 | uM | IL-1 alpha | 100 | ng/mL | 2 | LIF | 152.0 | 37 | |
RA2708 | IL-1 alpha | 100 | ng/mL | 2 | LIF | 150.0 | 41 | ||||
RA2159 | 5z-7-oxozeaenol | 0.6 | uM | Poly(I:C) | 2 | ug/mL | 2 | LIF | 39.5 | 38 | |
RA2159 | IKK16 | 2.0 | uM | Poly(I:C) | 2 | ug/mL | 2 | LIF | 34.0 | 25 | |
N2645 | 5z-7-oxozeaenol | 0.6 | uM | Poly(I:C) | 2 | ug/mL | 2 | LIF | 40.0 | 39 |